Nadifloxacin

Summary

Nadifloxacin (CHEMBL363449) is a phase-3 clinical-stage small-molecule antibacterial drug (ATC D10AF05); indicated across 1 condition including acne.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: D10AF05
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 360.4 Da · C19H21FN2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL363449
Name	Nadifloxacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4410
ChEBI	CHEBI:31889
ATC	D10AF05
Molecular formula	C19H21FN2O4
Molecular weight	360.4
InChIKey	JYJTVFIEFKZWCJ-UHFFFAOYSA-N

SMILES: CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O

IUPAC name: 7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Acuatim, Jinofloxacin, Nadifloxacin, Nadifloxacine, Nadifloxacino, NSC-759622, OPC 7251, OPC-7251, SID26758042, SID56463184, SID144205792, SID170465882

Patent coverage: 1,274 distinct patent families (4,480 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,419 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.15	Potency	707.9	nM	CHEMBL_ACT_3642795

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acne	3	MONDO:0011438	EFO:0003894

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00219570	PHASE4	COMPLETED	Dalacin-T Gel Post Approval Study
NCT00869492	PHASE3	UNKNOWN	Comparison of Nadifloxacin Cream Alone and With Benzoyl Peroxide Solution in the Treatment of Acne

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).